Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial

Xu, JP; Ling, HW; Geng, JL; Huang, YL; Xie, Y; Zheng, HP; Niu, HK; Zhang, TH; Yuan, J; Xiao, XH

Xiao, XH (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Endocrinol,Key Lab Endocrinol,Minist Hlth, 1 Shuaifuyuan Wangfujing, Beijing 100730, Peoples R China.

DIABETES OBESITY & METABOLISM, 2022; 24 (11): 2232

Abstract

Aim To evaluate the efficacy and safety of DBPR108 (prusogliptin), a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, as an add-on therapy in patients ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索